Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia 45Leukemia, Myeloid, Acute 33Congenital Abnormalities 30Leukemia, Lymphocytic, Chronic, B-Cell 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Breast Neoplasms 23Lymphoma, Follicular 21Lymphoma, B-Cell, Marginal Zone 21Lymphoma, Mantle-Cell 19Lymphoma, Large B-Cell, Diffuse 19Lymphoma 19Multiple Myeloma 18Lymphoma, Non-Hodgkin 18Myelodysplastic Syndromes 17Lymphoma, T-Cell, Cutaneous 15Lymphoma, Large-Cell, Immunoblastic 15Burkitt Lymphoma 15Sezary Syndrome 14Myeloproliferative Disorders 14Mycosis Fungoides 14Blast Crisis 14Leukemia, Myelomonocytic, Chronic 13Leukemia, Myeloid, Chronic-Phase 13Leukemia, Myeloid, Accelerated Phase 13Hodgkin Disease 13Waldenstrom Macroglobulinemia 10Primary Myelofibrosis 10Neoplasms, Plasma Cell 10Lymphoma, Large-Cell, Anaplastic 10Leukemia, Megakaryoblastic, Acute 10

Interventions

Irinotecan 31Paclitaxel 27Gemcitabine 27Cisplatin 25Docetaxel 20Oxaliplatin 16Fluorouracil 15alvocidib 13Leucovorin 13Carboplatin 13Capecitabine 12Bortezomib 10Early Intervention, Educational 9Topotecan 8Taxes 8Bevacizumab 73-aminopyridine-2-carboxaldehyde thiosemicarbazone 7ixabepilone 6Vorinostat 6Temozolomide 6Sorafenib 6Immunohistochemistry 6Immunoenzyme Techniques 67-hydroxystaurosporine 6tanespimycin 5Pharmacogenomic Testing 5Pemetrexed 5Magnetic Resonance Spectroscopy 5Filgrastim 5Etoposide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unspecified Adult Solid Tumor, Protocol Specific × Flow Cytometry × Clear all
NCT00372736 2023-08-04

AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors

Canadian Cancer Trials Group

Phase 1 Completed
27 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡